Category: Heart Valves
Heart Valves
Mitralign Inc. lands a $5 million credit facility from GE Capital it plans to use as working capital.
GE Capital's Healthcare Financial Services division gave Mitralign Inc. a $5 million line of credit.
Mitralign is developing a catheter-based mitral valve repair device.
The Tewksbury, Mass.-based firm plans to use the loan as working capital, according to a press release.
AGA Medical Inc.'s stock price falls 6 percent as a top investor, private equity firm Welsh, Carson, Anderson & Stowe trims its stake in the medical device maker.
By Thomas Lee
Shares of AGA Medical Holdings Inc. (NSDQ:AGAM) fell more than six percent May 11 after its top investor decided to divest a 10th of its holdings in the Plymouth, Minn.-based medical device maker.
Investors who backed ATS Medical Inc. stand to make significant gains if Medtronic Inc.'s planned $370 million buyout goes through.
By Thomas Lee
ATS Medical Inc. (NSDQ:ATSI) stock has been a dog for quite a while, never rising above $5 a share since 2004 after posting a high of $20 a share nine years ago. But some investors stand to profit handsomely from Medtronic Inc.’s (NYSE:MDT) proposed $370 million acquisition of the company.
Medtronic Inc. agrees to acquire Minneapolis peer ATS Medical Inc. for $370 million in cash and debt.
By Thomas Lee
Medtronic Inc. (NYSE:MDT) plans to acquire ATS Medical Inc. (NSDQ:ATSI) for $370 million in cash and debt, a move that further expands the medical device giant’s foray into the fast-growing market for products that treat structural heart disease.
Fridley, Minn.-based Medtronic will pay $4 for each share of ATS Medical, headquartered in Plymouth, Minn.
ATS Medical Inc. wins a nod from Health Canada for its Simulus mitral and tricuspid valve repair rings.
ATS Medical Inc. (NSDQ:ATSI) won a nod north of the border for its Simulus rings to repair defective heart valves.
The Minneapolis-based medical device maker said Health Canada, the Canadian equivalent of the Food & Drug Administration, cleared its mitral and tricuspid valve repair rings for sale in that country.
Medtronic Inc. launches a 1,000-patient study of its CoreValve aortic stenosis therapy, designed as a minimally invasive method of replacing faulty heart valves.
By Brandon Glenn
Medtronic Inc. (NYSE:MDT) launched what’s expected to be a 1,000-patient study of a catheter-based system it hopes will become a less-invasive — and highly lucrative — alternative to open-heart surgery for valve replacement.
Medtronic’s CoreValve system allows a replacement heart valve to be placed in a patient’s body via a catheter inserted in the femoral artery, near the groin. A catheter is a thin, flexible tube that can be inserted into a body cavity to open a passageway or to allow fluids to pass through.
